Catalyst Biosciences Inc reports results for the quarter ended in September - Earnings Summary

Gyre Therapeutics

16/11/2021 18:26

* Catalyst Biosciences Inc  CBIO.OQ  reported a quarterly
adjusted loss of 80 cents​​ per share for the quarter ended in
September. The mean expectation of five analysts for the quarter
was for a loss of 66 cents per share.
* Revenue rose 157.4% to $2.30 million from a year ago; 
analysts expected $675.00 thousand. 
* Catalyst Biosciences Inc's reported EPS for the quarter was a
loss of 80 cents​.
* The mean earnings estimate of analysts was unchanged in the
last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Catalyst Biosciences Inc shares had fallen by 59.4% this
quarter and lost 73.5% so far this year.
* The company reported a quarterly loss of $25.24 million.
* Wall Street's median 12-month price target for Catalyst
Biosciences Inc is $15.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
This summary was machine generated November 16 at 06:26 p.m.
 ​All figures in US dollars unless otherwise stated